These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31579608)

  • 21. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
    Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
    Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes.
    Rhee MH; Bayewitch M; Avidor-Reiss T; Levy R; Vogel Z
    J Neurochem; 1998 Oct; 71(4):1525-34. PubMed ID: 9751186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
    Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
    PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
    Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
    Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.
    Grassin-Delyle S; Naline E; Buenestado A; Faisy C; Alvarez JC; Salvator H; Abrial C; Advenier C; Zemoura L; Devillier P
    Br J Pharmacol; 2014 Jun; 171(11):2767-77. PubMed ID: 24467410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum.
    Selley DE; Cassidy MP; Martin BR; Sim-Selley LJ
    Mol Pharmacol; 2004 Nov; 66(5):1275-84. PubMed ID: 15286206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
    Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
    Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
    Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR
    J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
    Eldeeb K; Leone-Kabler S; Howlett AC
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
    Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG
    Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of the CB
    Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
    BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabinoid CB
    Spiller KJ; Bi GH; He Y; Galaj E; Gardner EL; Xi ZX
    Br J Pharmacol; 2019 May; 176(9):1268-1281. PubMed ID: 30767215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
    Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
    J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
    Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
    J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
    Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
    J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.